CBIO - Easy PFE IB6 ADC Upside Scenario Not Met, But 2L OS Trend Leaves Potential For CBIO's Differentiated ADC, Plus Combos Remain A Priority

Research evidence excerpt

CBIO - Easy PFE IB6 ADC Upside Scenario Not Met, But 2L OS Trend Leaves Potential For CBIO's Differentiated ADC, Plus Combos Remain A Priority

BIOTECHNOLOGY

CRESCENT BIOPHARMA, INC. June 22, 2026

Price targets are assigned for Buy- and Sell-rated stocks. Price targets for Neutral-rated stocks are provided at the discretion of the analyst.

Equity Valuation and Risks: For valuation methodology and risks associated with covered companies or price targets for covered companies, please

see the most recent company-specific research report at https://guggenheimlibrary.bluematrix.com/client/library.jsp, contact the primary analyst or your

Guggenheim Securities, LLC representative, or email GSResearchDisclosures@guggenheimpartners.com.

RATINGS DISTRIBUTIONS FOR GUGGENHEIM SECURITIES:

IB Serv./ Past 12Mos.

Rating Category Count Percent Count Percent

BUY 295 75.26% 80 27.12%

HOLD 96 24.49% 6 6.25%

SELL 1 0.26% 0 0.00%

Guggenheim Securities Research assigns Buy, Neutral, Sell ratings for covered securities. Such assignments equate to Buy, Hold and Sell for the purposes

of the above Rating Distribution Disclosure required by FINRA Rule 2241.

OTHER DISCLOSURES

This research is for our clients and prospective clients only. This research was prepared by personnel who are associated with both Guggenheim Securities,

LLC (a FINRA-registered broker-dealer, “Guggenheim Securities”) and Guggenheim Securities Research Services, LLC (an investment adviser, “GSRS,”

and together with Guggenheim Securities, “Guggenheim”). If you are paying separately for this research, it is being provided to you by GSRS. Otherwise, it

is being provided by Guggenheim Securities. Guggenheim does not create tailored or personalized research and all research provided by Guggenheim is

impersonal advice.